Scopus
YÖKSİS Eşleşti
Risk of metabolic syndrome in patients with bipolar disorder in Türkiye: A one-year follow-up study
International Journal of Psychiatry in Medicine · Ocak 2025
YÖKSİS Kayıtları
Risk of metabolic syndrome in patients with bipolar disorder in Türkiye: A one-year follow-up study
The International Journal of Psychiatry in Medicine · 2025 SCI-Expanded
DOKTOR ÖĞRETİM ÜYESİ RUKİYE TEKDEMİR →
Makale Bilgileri
DergiInternational Journal of Psychiatry in Medicine
Yayın TarihiOcak 2025
Scopus ID2-s2.0-105008079556
Özet
Objective: This study examined the incidence of metabolic syndrome (MetS) in 100 individuals with bipolar disorder (BD) and identified clinical and biological predictors of incident MetS during a 1-year follow-up. Methods: The study included euthymic BD type-1 patients consecutively recruited from outpatient clinics between July 2023 and July 2024. MetS was defined according to International Diabetes Federation criteria. Patients without MetS at baseline but with MetS during follow-up were classified as having incident MetS. A logistic regression model was utilized to estimate the adjusted odds ratios (OR) and corresponding 95% confidence intervals (CIs) for associations between predictors and incident MetS. Results: Of the 100 participants enrolled in the study (92% response rate), 29% met MetS criteria at baseline. Of the 71 without baseline MetS, 29 (40.8%) developed MetS over a 1-year period. Significant predictors of MetS onset included a higher number of manic/hypomanic episodes (OR = 1.459, 95% CI = 1.005-2.118, P =.047), increased chlorpromazine-equivalent antipsychotic dosages (OR = 1.007, 95% CI = 1.001-1.013, P =.024), high waist circumference (OR = 1.247, 95% CI = 1.052-1.479, P =.011), and hypertriglyceridemia (OR = 1.041, 95% CI = 1.007-1.077, P =.020). Conversely, lamotrigine use was inversely associated with MetS development (OR = 0.030, 95% CI = 0.001-0.659, P =.026). Conclusion: A high incidence of MetS (41%) was observed within 1 year among patients with BD. Identified risk factors highlight opportunities for intervention through mood recurrence prevention, careful pharmacotherapy management, and treatment of pre-existing components of MetS.
Yazarlar (5)
1
Rukiye Tekdemir
ORCID: 0000-0001-7912-5727
2
Fatih Ekici
ORCID: 0000-0003-4000-7429
3
Hasan Ali Guler
4
Muhammet Tuğrul Ergun
ORCID: 0000-0002-1802-302X
5
Yavuz Selvi
Anahtar Kelimeler
antipsychotics
bipolar disorders
longitudinal
metabolic syndrome
Kurumlar
Selçuk Üniversitesi
Selçuklu Turkey